Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Ipca Laboratories, Mumbai, India anil.pareek@ipca.com.
Anil
A
Pareek
Ipca Laboratories, Mumbai, India anil.pareek@ipca.com.
Nitin
N
Chandurkar
Ipca Laboratories, Mumbai, India anil.pareek@ipca.com.
Kumar
K
Naidu
D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000188:drug therapy; D051297:Sodium-Glucose Transporter 2
D001786:Blood Glucose; D005960:Glucosides; D007004:Hypoglycemic Agents; D051297:Sodium-Glucose Transporter 2